Bispecifics Webinar
Bispecifics Webinar
Formulating the Future of Bispecific Antibodies
Formulating the Future of Bispecific Antibodies
Cracking the Code: Smart Formulation
Strategies for Next-Gen Bispecifics
Free Webinar
October 28th, 2025
Register below:
Cracking the Code: Smart Formulation
Strategies for Next-Gen Bispecifics
Free Webinar
October 28th, 2025
Register below:
Overcoming the hidden challenges in bsAb drug product development
Bispecific antibodies are transforming drug development, but their complexity challenges conventional formulation.
High concentrations, stability risks, and subcutaneous delivery demand new approaches.
Bispecific antibodies are transforming drug development, but their complexity challenges conventional formulation. High concentrations, stability risks, and subcutaneous delivery demand new approaches.
Bispecific antibodies are transforming drug development, but their complexity challenges conventional formulation. High concentrations, stability risks, and subcutaneous delivery demand new approaches.
Join Our Expert-Led Webinar on October 28th to explore:
why bsAbs are uniquely difficult to formulate
how predictive tools (modeling, DoE) reduce formulation risk
how systematic excipient selection can save time and material
what to expect from a strategic formulation partner—not just a lab service
Join Our Expert-Led Webinar on October 28th to explore:
why bsAbs are uniquely difficult to formulate
how predictive tools (modeling, DoE) reduce formulation risk
how systematic excipient selection can save time and material
what to expect from a strategic formulation partner—not just a lab service
Want a deeper dive?
Download our white paper on bispecific formulations
Download our white paper on bispecific formulations
Our latest white paper explores:
· The critical pitfalls in bispecific formulation
· How data-driven strategies streamline excipient selection
· A real-world case study: stable, high-concentration bispecific for Phase 2 trials
Our latest white paper explores:
· The critical pitfalls in bispecific formulation
· How data-driven strategies streamline excipient selection
· A real-world case study: stable, high-concentration bispecific for Phase 2 trials
Contact
Ready to talk about your bispecific formulation strategy?
Our experts work with leading biotech companies to solve complex formulation challenges. If you’d like to discuss your molecule and explore tailored solutions, we’d be happy to connect.
Reach out now
Ulrike Konrad - VP Business Development
Ready to Talk About Your Bispecific Program?
Turning complex molecules into robust drug products
Ready to talk about your bispecific formulation strategy?
Turning complex molecules into robust drug products